Wendy Stevens
About
In The Last Decade
Wendy Stevens
111 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 85
- Pathology and Forensic Medicine 2.2k
- Pulmonary and Respiratory Medicine 1.2k
- Epidemiology 653
- Dermatology 595
- Immunology 523
Countries citing papers authored by Wendy Stevens
This map shows the geographic impact of Wendy Stevens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Stevens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Stevens more than expected).
Fields of papers citing papers by Wendy Stevens
This network shows the impact of papers produced by Wendy Stevens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Stevens. The network helps show where Wendy Stevens may publish in the future.
Co-authorship network of co-authors of Wendy Stevens
This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Stevens. A scholar is included among the top collaborators of Wendy Stevens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Stevens. Wendy Stevens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 5 | |
| 4 | 3 | |
| 5 | 0 | |
| 6 | 1 | |
| 7 | 4 | |
| 8 | 1 | |
| 9 | 7 | |
| 10 | 0 | |
| 11 | 6 | |
| 12 | 9 | |
| 13 | 4 | |
| 14 | 19 | |
| 15 | 12 | |
| 16 | The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. | 16 |
| 17 | Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. | 28 |
| 18 | Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. | 49 |
| 19 | 1 | |
| 20 | Survival and Predictors of Mortality In Australian Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.